START Center for Cancer Research (START) is a leading independent, early-phase oncology clinical research site network. START conducts preclinical and clinical trials using novel cancer therapeutics on behalf of pharmaceutical customers, bringing the high-quality research standards synonymous with the top academic medical centers to the community setting in which the vast majority of cancer patients are treated.
Investors 1
| Date | Name | Website |
| 03.06.2026 | Warburg Pi... | warburgpin... |
Mentions in press and media 1
| Date | Title | Description |
| 02.06.2026 | CV6 Therapeutics Appoints Dr. Chris Takimoto to Board as CV6-168 Advances Through Phase 1a | CV6 Therapeutics Chris Takimoto, MD, PhD. What attracted me to CV6 is the translational rationale underlying the program and its focus on enhancing the activity of therapies that remain central to cancer treatment.” — Chris Takimoto, MD, Ph... |